Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 1
2015 1
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

2 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Effect of Tumor Necrosis Factor Inhibitor Therapy on Osteoclasts Precursors in Ankylosing Spondylitis.
Perpétuo IP, Raposeiro R, Caetano-Lopes J, Vieira-Sousa E, Campanilho-Marques R, Ponte C, Canhão H, Ainola M, Fonseca JE. Perpétuo IP, et al. PLoS One. 2015 Dec 16;10(12):e0144655. doi: 10.1371/journal.pone.0144655. eCollection 2015. PLoS One. 2015. PMID: 26674064 Free PMC article.
INTRODUCTION: Ankylosing Spondylitis (AS) is characterized by excessive local bone formation and concomitant systemic bone loss. Tumor necrosis factor (TNF) plays a central role in the inflammation of axial skeleton and enthesis of AS patients. …
INTRODUCTION: Ankylosing Spondylitis (AS) is characterized by excessive local bone formation and concomitant systemic bone los …
Infliximab inhibits bone resorption by circulating osteoclast precursor cells in patients with rheumatoid arthritis and ankylosing spondylitis.
Gengenbacher M, Sebald HJ, Villiger PM, Hofstetter W, Seitz M. Gengenbacher M, et al. Ann Rheum Dis. 2008 May;67(5):620-4. doi: 10.1136/ard.2007.076711. Epub 2007 Aug 24. Ann Rheum Dis. 2008. PMID: 17720725
OBJECTIVE: To examine the effects of infliximab on bone resorption by osteoclast precursor cells (OCPs) in patients with rheumatoid arthritis (RA) and ankylosing spondylitis (AS) and to compare the results with changes in disease activity. ...Bl …
OBJECTIVE: To examine the effects of infliximab on bone resorption by osteoclast precursor cells (OCPs) in patients wit …
Feedback